Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed With Enhanced Host Conditioning
Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed With Enhanced Host Conditioning
Achilles Therapeutics提供晚期非小細胞肺癌和黑色素瘤中克隆新抗原反應性T細胞的1/2a期中期更新，包括首批接受增強宿主調節劑量的患者
- Improved VELOS manufacturing process delivering higher cNeT doses.
- Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
- First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment.
- 改進了 VELOS 製造工藝，可提供更高的 CNet 劑量。
- 協議已更新，以評估增強宿主條件的好處，預計將在2024年下半年提供更多數據。
- 前三名使用增強宿主化療的CHIRON和THETIS給藥的患者，以及符合標準TIL療法的IL-2患者的CNet持久性和植入量都有所改善。